Skip to main content
Pharnext logo

Pharnext — Investor Relations & Filings

Ticker · ALPHA ISIN · FR0011191287 LEI · 969500KJGF9ZUYXSMJ27 Euronext Growth Manufacturing
Open in API
Filings indexed 382 across all filing types
Latest filing 2024-04-30 Earnings Release
Country FR France
Listing Euronext Growth ALPHA

About Pharnext

https://pharnext.com/

Pharnext is an advanced clinical-stage biopharmaceutical company that develops novel therapeutics for neurodegenerative diseases lacking curative or satisfactory treatments. The company's approach is based on its proprietary Pleotherapy™ platform, which uses network pharmacology to identify and develop synergistic combinations of already-approved drugs at new, lower doses. This strategy aims to create more effective and safer treatments. Pharnext's lead product candidate, PXT3003, is an oral fixed-dose combination therapy in development for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A), a rare, debilitating inherited peripheral neuropathy.

Recent filings

Filing Released Lang Actions
Pharnext publie ses résultats 2023 et présente les avancées de la procédure de conciliation
Earnings Release Classification · 1% confidence The document is explicitly titled "Communiqué de presse" (Press Release) and announces the release of the 'rapport financier annuel 2023' (2023 annual financial report) along with updates on the conciliation procedure. Although it discusses the annual financial report and includes auditor comments (which might suggest an AR or 10-K), the primary function of this document is to announce the availability of those results and provide operational/financial highlights, which aligns perfectly with an Earnings Release (ER). It is not the full 10-K, nor is it just a standalone Audit Report (AR). It is the initial announcement of the period's results and key financial figures, making ER the most appropriate classification. The length (10,525 chars) is substantial but the format is that of a press release announcing results, not the full statutory report itself. FY 2023
2024-04-30 French
Pharnext a présenté les données de l'étude pivot de Phase III de PXT3003 dans la maladie de Charcot-Marie-Tooth de type 1A au congrès annuel de CMT-France
Regulatory Filings Classification · 1% confidence The document is explicitly titled "Communiqué de presse" (Press Release) and announces that Pharnext presented data from its Phase III study (PXT3003) at the annual CMT-France congress. It details the event, quotes management, and provides contact information for financial press/investor relations. This format—a brief announcement about an event or data presentation, rather than the full financial report (10-K, IR) or the presentation itself (IP)—is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it is focused on clinical data presentation at a conference, and not quarterly financial results, it fits best as a general announcement. Given the options, 'ER' (Earnings Release) is often used broadly for results announcements, but since this is a clinical data presentation announcement, 'RNS' (Regulatory Filings - general/miscellaneous) is a strong candidate, or potentially 'IP' if the content was the presentation itself. However, the text is a press release *about* the presentation, not the presentation slides or a formal earnings report. Because it is a press release announcing company activity (data presentation) and does not fit the specific definitions of 10-K, IR, or ER (which usually focuses on financial metrics), it defaults to the general regulatory announcement category. Revisiting the definitions: It is not an ER (no financial results summary), not an IP (it's a press release *about* the presentation), and not an AR (it's not a standalone audit report). It is a formal announcement of company activity. 'RNS' (Regulatory Filings) serves as the fallback for miscellaneous announcements. Given the context of a clinical update announcement, RNS is the most appropriate general classification.
2024-04-25 French
Information relative au nombre total de droits de vote et d'actions composant le capital social
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and its primary content is the announcement of the "nombre total de droits de vote et d'actions composant le capital social" (total number of voting rights and shares comprising the share capital) as of March 31, 2024, referencing French commercial code and AMF regulations (Article L.233-8 II du Code de commerce et article 223-16 du Règlement général de l'Autorité des Marchés Financiers). This type of mandatory periodic disclosure regarding share capital structure changes, often triggered by financing activities (like the mentioned OCEANE conversions and BSA exercises), is a specific type of regulatory update. While it relates to capital structure, it is a formal notification of share count rather than a general financing announcement (CAP) or a transaction in own shares (POS). Since it is a formal, required disclosure about the capital base, it fits best under Capital/Financing Update (CAP) or, if viewed as a general regulatory disclosure not covered elsewhere, Regulatory Filings (RNS). Given the specific focus on the total share count and voting rights, which is a key component of capital structure reporting, CAP is a strong candidate. However, the definitions provided do not have a specific code for 'Share Capital Disclosure'. Comparing the options: It is not an ER, IR, 10-K, or AR. It details capital changes resulting from financing instruments, making CAP relevant. But the core purpose is the mandatory disclosure of the share count itself. Since it is a formal regulatory announcement detailing capital structure changes, and 'Share Issue/Capital Change' (SHA) is defined as announcing *new share issues*, this document is reporting the *result* of those issues and the current total. Given the options, and recognizing this as a mandatory disclosure related to capital structure, 'CAP' (Capital/Financing Update) is the most appropriate fit among the provided choices, as it directly relates to the company's capital base changes detailed in the tables. If a more specific code for 'Share Capital Disclosure' existed, it would be preferred. Lacking that, CAP covers updates on capital structure changes.
2024-04-02 French
Ajustement de la valeur nominale
Share Issue/Capital Change Classification · 1% confidence The document is a press release ("Communiqué de presse") dated March 20, 2024, announcing a capital reduction ("réduction de capital") achieved by lowering the nominal value of the shares from 0.20 euro to 0.10 euro. This action directly impacts the company's capital structure and financing arrangements, as it is based on a resolution from the previous AGM. This clearly falls under the definition of 'Capital/Financing Update' (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. It is not a full annual report (10-K), an earnings release (ER), or a dividend notice (DIV).
2024-03-20 French
Pharnext fait un point complet sur sa situation opérationnelle, stratégique et financière
Legal Proceedings Report Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and provides a comprehensive update on the company's operational, strategic, and financial situation, including clinical trial results (PXT3003), ongoing negotiations for asset valuation, cost reduction plans, cash burn rate, debt structure, and the status of a conciliation procedure. It explicitly mentions that the company will continue to inform the market regularly as per its periodic and continuous disclosure obligations and states an objective to publish its 2023 annual accounts by April 30, 2024. This structure—a detailed update covering multiple facets of the business, released via a press release format, often preceding formal filings—is characteristic of an Earnings Release (ER) or a general update that might accompany or precede a more formal report. However, since it covers detailed financial status, operational strategy, and legal/financing updates in depth, it goes beyond a simple 'key highlights only' Earnings Release (ER). It is not a full Annual Report (10-K) or an Interim Report (IR) as it doesn't present structured financial statements for a specific period, but rather a status update. Given the comprehensive nature of the update covering strategy, financing, and clinical progress, it functions as a major corporate update. In the context of the provided definitions, this detailed status update, released as a press release, most closely aligns with an Earnings Release (ER) if it were tied to a reporting period, or potentially a Regulatory Filing (RNS) if it were purely informational. Since it discusses financial performance context (cash burn, debt) and future reporting (annual accounts target), ER is a strong candidate, but the content is broader than just earnings highlights. Because it is a comprehensive update on operations, strategy, and finance, and is explicitly a press release updating on recent events and future plans, it fits the description of an Earnings Release (ER) which often includes management commentary and outlook, even if it's not strictly quarterly results. Alternatively, since it is a broad update covering multiple regulatory/financial aspects, it could be RNS. Given the focus on financial status and operational outlook following recent events, ER is the most specific fit among the primary financial categories, although it is a very detailed one. If it were purely an announcement of a report, RPA would apply, but this document *is* the content update. I will classify it as an Earnings Release (ER) as it serves the function of communicating the company's current financial and operational standing to the market, even if it's not a formal quarterly filing. *Self-Correction/Refinement*: The document is a detailed operational and financial update released via press release, referencing past announcements and setting expectations for future reports (like the 2023 annual accounts). This type of comprehensive, non-periodic update often falls under the general disclosure category, but given the financial context (cash burn, financing negotiations), ER is usually reserved for results announcements. Since it is a detailed status update covering strategy, clinical trials, and finance, and is not a formal statutory report (10-K, IR), it functions as a major corporate disclosure. I will stick with ER as the best fit for a comprehensive financial/operational status update released via press release, or RNS as the fallback. Given the depth of financial status discussion, ER is slightly preferred over the generic RNS.
2024-03-11 French
Pharnext takes full stock of its operating, strategic and financial situation
Legal Proceedings Report Classification · 1% confidence The document is a comprehensive update from Pharnext SA detailing its clinical trial status (PREMIER trial for PXT3003), ongoing negotiations for operating rights, cost reduction plans, financial structure, and updates on previous shareholder meetings and conciliation procedures. It explicitly mentions the company's intention to 'continue to inform the market on a regular basis as part of its periodic and ongoing information obligations' and states a target date for publishing its '2023 financial statements by April 30, 2024, at the latest.' This structure—a detailed operational and financial status update released outside of a standard quarterly or annual filing deadline, often referencing previous press releases and future reporting dates—is characteristic of a general corporate update or press release. Since it is not a formal 10-K, IR, or ER, and it is a detailed narrative update rather than just an announcement of a report (RPA), it best fits the general 'Regulatory Filings' category (RNS) as a significant, ongoing disclosure, or potentially a Management Report (MDA) if it were more focused on management's explanation of results. Given the broad nature covering clinical, financial, and legal updates, and the context of continuous disclosure, RNS (Regulatory Filings/Miscellaneous Announcement) is the most appropriate fit for this type of detailed, non-standardized corporate status report.
2024-03-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.